New triple therapy shows promise in taming advanced tumors
NCT ID NCT03459222
First seen Apr 09, 2026 · Last updated May 20, 2026 · Updated 5 times
Summary
This study tested a combination of three drugs (relatlimab, nivolumab, and either BMS-986205 or ipilimumab) in 229 people with advanced solid tumors that could not be cured. The goal was to see if the triple therapy was safe and could shrink or control the cancer. Participants had to have measurable disease and good performance status, but those with brain metastases were excluded.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Local Institution - 0001
Germantown, Tennessee, 38138, United States
-
Local Institution - 0003
Aurora, Colorado, 80045, United States
-
Local Institution - 0004
Baltimore, Maryland, 21231, United States
-
Local Institution - 0005
St Louis, Missouri, 63110, United States
-
Local Institution - 0006
Duarte, California, 91010, United States
-
Local Institution - 0007
Zurich, 8091, Switzerland
-
Local Institution - 0008
Lausanne, 1011, Switzerland
-
Local Institution - 0009
Naples, 80131, Italy
-
Local Institution - 0010
Forlì, 47014, Italy
-
Local Institution - 0011
Nedlands, Western Australia, 6009, Australia
-
Local Institution - 0012
Wollstonecraft, New South Wales, 2065, Australia
-
Local Institution - 0013
Headington, OX3 7LE, United Kingdom
-
Local Institution - 0014
Newcastle upon Tyne, NE7 7DN, United Kingdom
-
Local Institution - 0015
Villejuif, 94800, France
-
Local Institution - 0016
Toulouse, 31059, France
-
Local Institution - 0017
Marseille, 13385, France
-
Local Institution - 0018
Madrid, 28050, Spain
-
Local Institution - 0019
Barcelona, 08036, Spain
-
Local Institution - 0020
Pamplona, 31008, Spain
-
Local Institution - 0021
Madrid, 28041, Spain
-
Local Institution - 0022
Málaga, 29011, Spain
-
Local Institution - 0023
Rome, 00144, Italy
Conditions
Explore the condition pages connected to this study.